Merck


Streamlined and focused

24/11/21 -"This looks to be the new motto of Merck’s refurbished R&D pipeline. The strong cut in clinical programmes (50% up to 11/11/2021) has been quietly done. This reminds us of 2014/15, when Merck did ..."

Pages
82
Language
English
Published on
24/11/21
You may also be interested by these reports :
07/12/21
According to media reports, CSL plans to acquire Vifor Pharma. Both firms operate in different therapeutic areas and, hence, there are no major ...

06/12/21
Omicron did not come fully out of the blue as we had pointed out the risk of new mutations coming from regions with lower vaccination rates. After ...

04/12/21
The recent surge of the more-contagious Omicron variant could result in delayed recovery for plasma supplies. Remember, with various preliminary ...

03/12/21
Given the multiple near-term challenges, including the DoJ investigation w.r.t Entresto (currently second-largest drug in terms of sales) and Omicron ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO